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ABSTRACT
Anemia of chronic disease (ACD) frequently occurred in patients with chronic inflammatory diseases and can be treated 
by treating the underlying disease. On the other hand, iron-deficiency anemia (IDA), the most common type of anemia, 
occurred with iron loss or when the iron requirement of the body was increased. Since the treatment methods for ACD 
and IDA differ, it is important to clinically distinguish between the two types of anemia. In this study, we investigated and 
evaluated the performance of a number of biomarkers, including ferritin, soluble transferrin receptor (sTfR), hepcidin, 
C-reactive protein (CRP) and combination markers containing ferritin for the diagnosis of IDA using serum samples from 
Korean patients (80 ACD and 48 IDA Korean patients). Among the single markers, ferritin exhibited the best performance 
with 98.58% AUC and 97.50% sensitivity. In this study, a combination of two biomarkers was used to differentially 
diagnose IDA and ACD. Among the combination markers, ferritin + sTfR showed the best performance with 99.51% AUC 
and 98.75% sensitivity. We found that the ferritin + sTfR combination showed the best diagnostic performance with 
1.25% higher SN than ferritin alone. Moreover, it also showed 10% better diagnostic performance than the single ferritin 
marker within the data range where the distinction between ACD and IDA is unclear. We propose that using combination 
markers containing ferritin may diagnose IDA more accurately and facilitate the determination of the appropriate anemia 
treatment to expedite patient recovery. 
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ABSTRAK
Anemia penyakit kronik (ACD) kerap berlaku kepada pesakit dengan penyakit radang kronik dan boleh dirawat dengan 
merawat penyakit yang mendasarinya. Sebaliknya, anemia kekurangan zat besi (IDA) adalah jenis anemia yang paling 
biasa berlaku dengan  kehilangan zat besi atau apabila keperluan zat besi dalam badan bertambah. Oleh kerana kaedah 
rawatan untuk ACD dan IDA berbeza, adalah penting secara klinikal untuk membezakan antara kedua-dua jenis anemia. 
Dalam kajian ini, kami mengkaji dan menilai prestasi beberapa penanda biologi, termasuk feritin, transferin larut 
reseptor (sTfR), hepcidin, protein C-reaktif (CRP) dan penanda gabungan yang mengandungi feritin untuk diagnosis 
IDA menggunakan sampel serum daripada pesakit warga Korea (80 ACD dan 48 IDA pesakit warga Korea). Antara 
penanda tunggal, feritin menunjukkan prestasi yang terbaik dengan 98.58% AUC dan 97.50% kepekaan. Dalam kajian 
ini, gabungan dua penanda biologi telah digunakan untuk mendiagnosis IDA dan ACD secara berbeza. Antara penanda 
kombinasi, feritin + sTfR menunjukkan prestasi yang terbaik dengan 99.51% AUC dan 98.75% kepekaan. Kami mendapati 
bahawa gabungan feritin + sTfR menunjukkan prestasi diagnostik yang terbaik dengan 1.25% SN lebih tinggi daripada 
feritin sahaja. Selain itu, ia juga menunjukkan prestasi diagnostik 10% lebih baik daripada penanda feritin tunggal 
dalam julat data dengan perbezaan antara ACD dan IDA adalah tidak jelas. Kami mencadangkan bahawa penggunaan 
penanda gabungan yang mengandungi feritin boleh mendiagnosis IDA dengan lebih tepat dan memudahkan penentuan 
rawatan anemia yang sesuai untuk mempercepatkan pemulihan pesakit.
Kata kunci: Anemia kekurangan zat besi; indeks; pelbagai analit; serum transferin
INTRODUCTION
Anemia, a commonly occurring disease, is associated 
with low levels of red blood cells or hemoglobin and is 
known to affect one in 24 Americans. It is caused by the 
decreased production of red blood cells or hemoglobin, 
damage or destruction of red blood cells, chronic diseases 
and malignant tumors (MedicineNet.com). Anemia of 
chronic disease (ACD) frequently occurred in patients 
with chronic inflammatory diseases and can be treated by 
treating the underlying disease. On the other hand, iron-
deficiency anemia (IDA), the most common type of anemia, 
occurred with iron loss or when the iron requirement of the 
body was increased. In the developed world, IDA shows a 
prevalence of 2-5% among adult men and post-menopausal 
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women, constitutes a common cause of referral to 
gastroenterologists (Calvey & Castleden 1987; Mclntyre & 
Long 1993). IDA has various physiological or pathological 
causes, which are important criteria for determining the 
precise treatment regimen of anemia (Clark 2009). For 
instance, blood loss from the gastrointestinal (GI) tract 
or menstrual blood loss commonly cause IDA in adult 
men and post-menopausal or in pre-menopausal women, 
respectively (Calvey & Castleden 1987; Mclntyre & Long 
1993).
 Iron is an essential nutrient for physiological processes 
such as oxygen transportation and cellular respiration. 
It is an important co-factor for various proteins such as 
hemoglobin, myoglobin and in heme complexes such as 
cytochromes. Iron deficiency can not only cause anemia, 
but may also affect nerve function and intelligence; thus, it 
is a serious disorder, especially in infants. Conversely, iron 
overload can cause problems such as hemochromatosis, 
hepatocirrhosis, diabetes, cardiomyopathy, arthritis and 
skin disease. Both iron deficiency and overload can be 
prevented by testing for the iron levels. While dietary iron 
supplementation may be helpful for IDA patients, it can 
prove harmful for ACD patients.
 Since the treatment methods for ACD and IDA differ, it 
is important to clinically distinguish between the two types 
of anemia; however, making this distinction is challenging 
due to the low levels of serum iron and transferrin 
saturation exhibited by both ACD and IDA (Theurl et al. 
2009). Especially in hospital, iron deficiency is clinically 
associated with inflammation and the typical iron pattern 
of IDA and ACD appears at the same time (Remacha et al. 
1998).
 The current gold standard for the diagnosis of IDA is 
bone marrow examination. Due to the invasive and costly 
nature of this method, efforts to develop novel, simpler, 
non-invasive in vitro diagnostic tests for IDA are ongoing 
(Chang et al. 2007; Geerts et al. 2012; Goyal et al. 2008; 
Lipschitz et al. 1974; Punnonen et al. 1997; Weiss & 
Goodnough 2005).
 Ferritin is a biomarker commonly used to differentially 
diagnose IDA and ACD. Ferritin, an iron-storing protein is 
used as an indirect indicator of the total iron concentration 
in the body. IDA is diagnosed when the ferritin levels are 
<30 ng/mL, whereas in ACD, the ferritin levels are >100 
ng/mL. However, patients with infection, inflammatory 
responses, or malignant tumors may also exhibit high levels 
of ferritin, making it difficult to diagnose IDA using ferritin 
alone (Lipschitz et al. 1974; Weiss & Goodnough 2005). 
Thus, numerous efforts have been undertaken to develop 
methods for differentiating between and diagnosing IDA 
and ACD using various combinations of inflammation-
related serum proteins.
 Soluble transferrin receptor (sTfR) is an indicator of 
the intracellular iron levels. Similar to ferritin, it is not 
affected by chronic diseases and has been reported to 
be a useful indicator of stored iron levels (MedicineNet.
com; Chang et al. 2007; Geerts et al. 2012). C-reactive 
protein (CRP), an inflammatory response protein is used to 
identify patients with infections, inflammatory responses or 
malignant tumors, whereas the peptide hormone hepcidin 
is a regulator of iron homeostasis (Geerts et al. 2012).
 In this study, we combined ferritin with the 
complementary biomarkers in an attempt to establish an 
accurate diagnostic method of IDA.
MATERIALS AND METHODS
STUDY POPULATIONS AND SAMPLE COLLECTION 
The serum samples used in this study were obtained from 
128 Korean anemic patients from the Hallym University 
Medical Center. The patient groups comprised of 80 ACD 
patients and 48 IDA patients.
IMMUNOASSAYS 
Protein levels were measured using xMAP bead-based 
technology (Luminex, Austin, TX). The sera obtained 
from the anemic patients were incubated with Luminex-
beads covered with ferritin, sTfR, hepcidin and CRP. The 
fluorescence levels of the antibodies from each bead were 
measured and calculated using standard curves created by 
Bio-Rad (five-parameter curve fitting). The Luminex xMAP 
technology is a multiplexed immunoassay measurement 
method that examines multiple biomarkers simultaneously 
making it superior in terms of cost, time and amount of 
samples processed, relative to other individual examination 
methods.
STATISTICAL ANALYSIS 
Statistical analyses and performance measurements of the 
biomarkers were performed using the in-house-developed 
multi-biomarker analytical system (Cheong et al. 2013). 
The model used to differentiate between IDA and ACD must 
have the ability to test for both, the sensitivity (SN) and 
specificity (SP). A common method to test for adequately 
high SN and SP values is to calculate the area under the 
receiver operating characteristic curve (ROC-AUC) (Pepe 
et al. 2006). For performance measurements, AUC, SN and 
SP were determined by leave-one-out validations using a 
logistic regression classification algorithm.
RESULTS AND DISCUSSION
Figure 1 shows the box plots of IDA and ACD distributions 
for the individual biomarkers. In the ACD and IDA groups, 
the median ferritin concentrations are 111 μg/mL (mean±SD, 
111±54.95 μg/mL) and 7 μg/mL (11.38±10.13 μg/mL); 
median sTfR concentrations are 11.65 μg/mL (11.67±4.78 
μg/mL) and 32.36 μg/mL (38.4±23.28 μg/mL); median 
CRP concentrations are 19.35 pg/mL (38.92±56.71 pg/
mL) and 3.18 pg/mL (14.61±26.88 pg/mL); and median 
hepcidin concentrations are 5.92 μg/mL (10.52±11.6 μg/
mL) and 1.25 μg/mL (2.31±3.24 μg/mL), respectively. 
In the case of ferritin, ACD patients exhibit a wide range 
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of distribution from 20-200 μg/mL, whereas IDA patients 
exhibit a relatively narrow distribution. ACD and IDA patients 
exhibit significantly distinct levels of ferritin and sTfR. In 
the case of CRP and hepcidin, differentiation of the median 
levels is negligible between the ACD and IDA patients.
 Figure 2 depicts two-dimensional (2D) scatter plots 
of ferritin and other markers and clearly demonstrates the 
marker distribution for ACD and IDA. Figure 2(a), a scatter 
plot of ferritin and sTfR, shows that classification of ACD 
and IDA is more clear than scatter plots of ferritin/CRP 
(Figure 2(b)) and ferritin/hepcidin (Figure 2(c)). 
 Figure 3 shows the ROC curves for the single markers 
used to test for IDA diagnostic performance. Table 1 shows 
the calculated values of area under the receiver operating 
characteristic curve (ROC-AUC) and sensitivity (SN) using 
a 90% cutoff-point for specificity (SP). Among the single 
FIGURE 1. Box plots of the individual markers of ACD, anemia of chronic disease; IDA, iron deficiency anemia; 
sTfR, soluble transferrin receptor; and CRP, C-reactive protein
FIGURE 2. 2D scatter plots of ferritin combination markers (a) Ferritin and soluble transferrin receptor (sTfR), 
(b) ferritin and C-reactive protein (CRP) and (c) ferritin and hepcidin
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markers, ferritin exhibited the best performance with 98.58% 
AUC and 97.50% SN. sTfR showed a weaker performance 
than ferritin with 95.78% AUC and 81.25% SN. AUC and SN 
values for hepcidin and CRP were 83.72 and 42.50% and 
68.76 and 23.75%, respectively, indicating that they are 
relatively poor diagnostic markers for anemia. Since these 
markers provide information regarding inflammation, they 
can be used as combination markers with anemia-related 
markers.
 In this study, a combination of two biomarkers was 
used to differentially diagnose IDA and ACD. Ferritin, the 
most commonly used marker for anemia, shows the best 
performance in differentiating between IDA and ACD. In this 
study, ferritin was combined with the other markers. Figure 
4 shows the ROC curves of these combination markers and 
Table 2 shows their ROC-AUC and SN values.
 Among the combination markers, ferritin + sTfR 
showed the best performance with 99.51% AUC and 98.75% 
SN. Ferritin + CRP showed 99.22% AUC and 97.50% SN, 
whereas ferritin + hepcidin showed 98.49% AUC and 
95.00% SN. Ferritin + sTfR and ferritin + CRP exhibited 
similar 95% confidence intervals (CI) of 97.83-100.0 and 
97.30-99.83, respectively, indicating a strong diagnostic 
performance of both of these combinations.
TABLE 1. ROC-AUC comparison of the single markers of anemia
Marker AUC 95% CI SN at 90% SP
Ferritin
sTfR
Hepcidin
CRP
98.58
95.78
83.72
68.76
96.24~99.58
98.31~91.22
73.88~89.91
59.00~77.41
97.50
81.25
42.50
23.75
FIGURE 3. ROC curves for ferritin, soluble transferrin receptor (sTfR), 
hepcidin and C-reactive protein (CRP)
FIGURE 4. ROC curves for combination markers of anemia
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 Due to the difficulty in differentiating between 
ACD and IDA with ferritin values of 10-100 ng/mL, the 
data within this range were sampled and compared for 
diagnostic performance.
 Figure 5 shows the ROC curves for ferritin as a single 
marker and combination markers containing ferritin, 
between the ferritin values of 10-100 ng/mL. Table 3 
compares their ROC-AUC and SN performance.
 Within the data range, the ferritin single marker 
had an ROC-AUC value of 94.49% and SN of 77.78%. In 
addition, the ferritin + sTfR combination showed the best 
performance with 99.48% AUC and 97.78% SN, which 
is similar to its performance in the overall data. Also, 
ferritin + CRP and ferritin + hepcidin showed 96.97 and 
94.04% AUC and 95.55 and 77.78% SN, respectively, which 
indicates a weaker performance, compared to their overall 
data.
 The ROC curve in Figure 6(a) shows that ferritin and 
ferritin + sTfR exhibit the best performance among the 
single and combination markers, respectively. The ROC 
curve in Figure 6(b) exhibits the performance of limited 
ferritin data between 10-100 ng/mL. Ferritin and ferritin + 
sTfR exhibit 98.58 and 99.51% AUC and 97.5 and 98.75% 
sensitivity, respectively. In other words, the performance of 
the combination markers was increased by 1% compared to 
the ferritin marker alone. The combination of ferritin and 
sTfR shows the highest AUC and 95% CI for both the single 
and combination markers. Limited Ferritin combination 
from 10-100 ng/mL has 98.05% on AUC and 97.14% on 
sensitivity. Although the sample size of this data was 
smaller than the unlimited data, ferritin as a single marker 
has only 1.5% difference with the combination of ferritin 
and sTfR.
CONCLUSION
In this study, the performance of ferritin, sTfR, hepcidin and 
CRP as single markers and combination markers containing 
ferritin, was tested to determine the most accurate 
diagnostic method for IDA. We found that the ferritin + 
sTfR combination showed the best diagnostic performance 
with 1.25% higher SN than ferritin alone. Moreover, it also 
showed 10% better diagnostic performance than the single 
ferritin marker within the data range where the distinction 
between ACD and IDA is unclear. The physiological and 
pathological causes of IDA are diverse and they become 
TABLE 2. ROC-AUC comparison of combination markers of anemia
Marker AUC 95% CI SN at 90% SP
Ferritin+sTfR
Ferritin+CRP
Ferritin+Hepcidin
99.51
99.22
98.49
97.83-100.0
97.30-99.83
96.28-99.50
98.75 
97.50 
95.00
TABLE 3. ROC-AUC comparison of combination markers for ferritin data range (10-100 ng/mL)
Marker AUC 95% CI SN at 90% SP
Ferritin
Ferritin+ sTfR
Ferritin+CRP
Ferritin+Hepcidin
94.49
98.48
96.97
94.04
86.77-98.14
94.03-100.0
90.95-99.49
86.15-97.63
77.78
97.78
95.56
77.78
FIGURE 5. ROC curves of ferritin data range (10-100 ng/mL)
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important evaluation criteria when selecting the most 
appropriate treatment regimen for anemia. Therefore, 
using combination markers containing ferritin and other 
markers related to the diverse causes of IDA, may diagnose 
IDA more accurately and facilitate the determination of the 
appropriate anemia treatment to expedite patient recovery. 
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